Press Release: LanzaTech Announces First Quarter 2025 Financial Results

Dow Jones
05-19

CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (NASDAQ: LNZA) ("LanzaTech" or the "Company"), a carbon management solutions company, today reported its financial and operating results for the first quarter of 2025.

Key Takeaways:

   -- Reported total revenue of $9.5 million for the first quarter of 2025 as 
      compared to $10.2 million for the first quarter of 2024. The 
      year-over-year decrease was driven primarily by lower revenues in the 
      biorefining and Joint Development Agreement ("JDA") & Contract Research 
      businesses, which was largely offset by a significant increase in 
      CarbonSmart$(TM)$ revenue. 
 
   -- Continued to shift the Company's core operations from research and 
      development to the global deployment of LanzaTech's commercially proven 
      technology, with incremental actions being taken to sharpen the business 
      focus, streamline operations, and improve the Company's cost structure. 
 
   -- Closed $40 million of preferred equity capital in May of 2025; however, 
      after completing its assessment as required by Generally Accepted 
      Accounting Principles ("GAAP"), management has concluded that its 
      continuing actions such as ongoing liquidity initiatives, together with 
      the terms of the preferred capital, and the execution of cost reduction 
      plans, do not alleviate substantial doubt about the Company's ability to 
      continue as a going concern. 

First Quarter 2025 Financial Results

The table below outlines key results for the first quarter of 2025:

 
All amounts in millions ($)        Three Months Ended March 31, 
                              -------------------------------------- 
                                     2025                2024 
                                                      ---------- 
Revenue                        $         9.5       $        10.2 
Cost of revenue                          7.5                 6.8 
Gross Profit                             2.0                 3.4 
Operating expenses                      33.0                29.6 
Net loss                               (19.2)              (25.5) 
Adjusted EBITDA loss (1)       $       (30.5)      $       (22.1) 
 
 

(1) See "Non-GAAP Financial Measures" and "Reconciliations of GAAP Net Loss to Adjusted EBITDA" sections herein for an explanation and reconciliations of non-GAAP measures used throughout this release.

Revenue

   -- Reported total revenue of $9.5 million for the first quarter of 2025 as 
      compared to total revenue of $10.2 million for the first quarter of 2024. 
      The decrease was driven primarily by lower biorefining and JDA & Contract 
      Research revenues year-over-year, which were offset by a significant 
      increase in CarbonSmart revenue: 
 
          -- Biorefining revenue for the first quarter of 2025 was $2.9 million 
             as compared to $5.0 million for the first quarter of 2024. The 
             year-over-year decrease was driven primarily by the first quarter 
             of 2024 benefiting from engineering and other services contracts 
             with existing customers which have since reached the completion of 
             their current development phase. 
 
          -- JDA & Contract Research revenue for the first quarter of 2025 was 
             $2.4 million as compared to $4.3 million for the first quarter of 
             2024. The year-over-year decline was attributable to the 
             completion of certain government projects during 2024, compounded 
             by a period of downtime prior to new projects commencing. 
 
          -- CarbonSmart revenue for the first quarter of 2025 was $4.2 million 
             as compared to $0.9 million for the first quarter of 2024. The 
             year-over-year increase was attributable to incremental direct 
             fuel sales as a result of establishing licensing arrangements, 
             identifying partners, and developing supply chain infrastructure 
             during the third quarter of 2024. 

Cost of Revenue

   -- For the first quarter of 2025, the cost of revenue was $7.5 million as 
      compared to $6.8 million for the first quarter of 2024. The 
      year-over-year increase was driven in part by a change in revenue mix 
      related to a rise in revenue generated by CarbonSmart, which is a lower 
      margin business as compared to biorefining and JDA & Contract Research. 
      Additionally, the biorefining business experienced margin contraction 
      during the first quarter of 2025 as compared to the same period in 2024 
      as a result of customer mix. 

Operating Expenses

   -- For the first quarter of 2025, operating expenses were $33.0 million as 
      compared to $29.6 million for the first quarter of 2024. The 
      year-over-year increase was primarily driven by incremental costs 
      associated with sharpening the business focus, streamlining operations, 
      and evaluating strategic options. 

Net Loss

   -- For the first quarter of 2025, net losses were $19.2 million as compared 
      $25.5 million for the first quarter of 2024. Net loss decreased 
      year-over-year primarily as a result of a $17.9 million non-cash gain on 
      financial instruments being recorded in the first quarter of 2025, that 
      was partially offset by expenses incurred associated with evaluating 
      strategic options and a $6.5 million non-cash loss recorded related to 
      equity method investees. 

Adjusted EBITDA Loss

   -- For the first quarter of 2025, adjusted EBITDA loss was $30.5 million as 
      compared to $22.1 million for the first quarter of 2024. The increase in 
      adjusted EBITDA loss year-over-year was primarily attributable to higher 
      selling, general and administrative expenses as a result of evaluating 
      strategic options, along with lower revenue and higher cost of sales 
      period-over-period. 

Balance Sheet and Liquidity

As of March 31, 2025, LanzaTech had $23.4 million in total cash, restricted cash, and investments, compared to total cash of $58.1 million at the end of December 31, 2024. The Company subsequently closed $40 million of preferred equity capital in May of 2025.

About LanzaTech

LanzaTech Global, Inc. (NASDAQ: LNZA) is the carbon recycling company transforming waste carbon into sustainable fuels, chemicals, materials, and protein. Using its biorecycling technology, LanzaTech captures carbon generated by energy-intensive industries at the source, preventing it from being emitted into the air. LanzaTech then gives that captured carbon a new life as a clean replacement for virgin fossil carbon in everything from household cleaners and clothing fibers to packaging and fuels. For more information about LanzaTech, please visit https://lanzatech.com.

Forward Looking Statements

This press release includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of LanzaTech. These statements are based on the beliefs and assumptions of LanzaTech's management. Although LanzaTech believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, LanzaTech cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words "believes," "estimates," "expects," "projects," "forecasts," "may," "will," "should," "seeks," "plans," "scheduled," "anticipates," "intends" or similar expressions. The forward-looking statements are based on projections prepared by, and are the responsibility of, LanzaTech's management. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside LanzaTech's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements, including the Company's ability to continue operations as a going concern; the Company's ability to obtain the stockholder approvals necessary to consummate the subsequent equity financing contemplated by the Series A Convertible Senior Preferred Stock Purchase Agreement, dated May 7, 2025; the Company's ability to attract new investors and raise substantial additional financing to fund its operations and/or execute on its other strategic options; the Company's ability to regain compliance with the listing rules of Nasdaq and maintain the listing of its securities on Nasdaq; and the Company's ability to achieve profitability. LanzaTech may be adversely affected by other economic, business, or competitive factors, and other risks and uncertainties, including those described under the header "Risk Factors" in its Form 10-K for the year ended December 31, 2024, its Form 10-Q for the quarter ended March 31, 2025 and in future SEC filings. New risk factors that may affect actual results or outcomes emerge from time to time and it is not possible to predict all such risk factors, nor can LanzaTech assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to LanzaTech or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. LanzaTech undertakes no

obligations to update or revise publicly any forward-looking statements.

Non-GAAP Financial Measures

To supplement our financial statements presented in accordance with US GAAP and to provide investors with additional information regarding our financial results, we have presented adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is not based on any standardized methodology prescribed by US GAAP and is not necessarily comparable to similarly titled measures presented by other companies.

We define adjusted EBITDA as our net loss, excluding the impact of depreciation, interest income, net, stock-based compensation expense, change in fair value of warrant liabilities, change in fair value of Brookfield SAFE liabilities, loss on Brookfield SAFE extinguishment, change in fair value of the FPA Put Option and Fixed Maturity Consideration liabilities, change in fair value of our outstanding convertible note and related transaction costs, change in fair value of Brookfield Loan and(loss) gain from equity method investees. We monitor adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets, and to develop operational goals for managing our business. We believe adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of certain expenses that we include in net loss. Accordingly, we believe adjusted EBITDA provides useful information to investors, analysts, and others in understanding and evaluating our operating results and enhancing the overall understanding of our past performance and future prospects.

Adjusted EBITDA is not prepared in accordance with US GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with US GAAP. There are a number of limitations related to the use of adjusted EBITDA rather than net loss, which is the most directly comparable financial measure calculated and presented in accordance with US GAAP. For example, adjusted EBITDA: (i) excludes stock-based compensation expense because it is a significant non-cash expense that is not directly related to our operating performance; (ii) excludes depreciation expense and, although this is a non-cash expense, the assets being depreciated and amortized may have to be replaced in the future; (iii) excludes gain or losses on equity method investee; and (iv) excludes certain income or expense items that do not provide a comparable measure of our business performance. In addition, the expenses and other items that we exclude in our calculations of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results. In addition, other companies may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.

 
 
                         LANZATECH GLOBAL INC. 
                       CONSOLIDATED BALANCE SHEETS 
          (Unaudited, in thousands, except share and per share 
                                  data) 
 
                                            March 31,     December 31, 
                                            ----------  ---------------- 
                                               2025           2024 
                                             --------       --------- 
Assets 
Current assets: 
   Cash and cash equivalents                $  13,778    $     43,499 
   Held-to-maturity investment securities       7,411          12,374 
   Trade and other receivables, net of 
    allowance                                   9,058           9,456 
   Contract assets                             13,267          18,975 
   Other current assets                        14,157          15,030 
                                             --------       --------- 
      Total current assets                     57,671          99,334 
Property, plant and equipment, net             20,225          22,333 
Right-of-use assets                            28,482          26,790 
Equity method investment                           --           4,363 
Equity security investment                     14,990          14,990 
Other non-current assets                        4,467           6,873 
                                             --------       --------- 
      Total assets                          $ 125,835    $    174,683 
                                             --------       --------- 
Liabilities and Shareholders' Equity 
Current liabilities: 
   Accounts payable                         $   6,434    $      5,289 
   Other accrued liabilities                    7,506           8,876 
   Warrants                                       549           3,531 
   Fixed Maturity Consideration and 
    current FPA Put Option liability            4,123           4,123 
   Contract liabilities                         5,291           6,168 
   Accrued salaries and wages                   2,451           2,302 
   Current lease liabilities                      166             158 
                                             --------       --------- 
      Total current liabilities                26,520          30,447 
Non-current lease liabilities                  30,144          30,619 
Non-current contract liabilities                5,433           5,233 
FPA Put Option liability                       30,015          30,015 
Brookfield SAFE liability                          --          13,223 
Brookfield Loan liability                      18,416              -- 
Convertible Note                               15,969          51,112 
Other long-term liabilities                       512             587 
                                             --------       --------- 
      Total liabilities                       127,009         161,236 
 
Shareholders' Equity 
Common stock, $0.0001 par value, 
 600,000,000 and 600,000,000 shares 
 authorized; 197,897,580 and 194,915,711 
 shares issued and outstanding as of March 
 31, 2025 and December 31, 2024, 
 respectively                                      19              19 
Additional paid-in capital                    983,991         981,638 
Accumulated other comprehensive income          3,648           1,393 
Accumulated deficit                          (988,832)       (969,603) 
                                             --------       --------- 
      Total shareholders' equity               (1,174)         13,447 
                                             --------       --------- 
      Total liabilities and shareholders' 
       equity                               $ 125,835    $    174,683 
                                             ========       ========= 
 
 
 
                         LANZATECH GLOBAL INC. 
                  CONSOLIDATED STATEMENTS OF OPERATIONS 
          (Unaudited, in thousands, except share and per share 
                                  data) 
 
                                         Three Months Ended March 31, 
                                      ---------------------------------- 
                                              2025           2024 
                                                          ----------- 
Revenues: 
   Contracts with customers and 
    grants                             $         3,057   $      6,250 
   CarbonSmart product sales                     4,204            863 
   Collaborative arrangements                    1,050          2,223 
   Related party transactions                    1,172            908 
                                          ------------    ----------- 
      Total revenues                             9,483         10,244 
Costs and operating expenses: 
Contracts with customers and 
 grants(1)                                       2,902          4,998 
CarbonSmart product sales(1)                     4,136            919 
Collaborative arrangements(1)                      461            796 
Related party transactions(1)                       14             57 
   Research and development expense             16,494         17,061 
   Depreciation expense                            781          1,530 
   Selling, general and 
    administrative expense                      15,748         11,037 
                                          ------------    ----------- 
      Total cost and operating 
       expenses                                 40,536         36,398 
                                          ------------    ----------- 
Loss from operations                           (31,053)       (26,154) 
Other income (expense): 
   Interest income, net                            438          1,148 
   Other income, net                            17,918            179 
                                          ------------    ----------- 
      Total other income, net                   18,356          1,327 
                                          ------------    ----------- 
Loss before income taxes                       (12,697)       (24,827) 
Income tax expense                                  --             -- 
Loss from equity method investees, 
 net                                            (6,532)          (681) 
                                          ------------    ----------- 
Net loss                               $       (19,229)  $    (25,508) 
                                          ============    =========== 
 
Other comprehensive loss: 
   Changes in credit risk of fair 
   value instruments                             2,696             -- 
   Foreign currency translation 
    adjustments                                   (441)            42 
                                          ------------    ----------- 
Comprehensive loss                     $       (16,974)  $    (25,466) 
                                          ============    =========== 
 
Net loss per common share - basic 
 and diluted                           $         (0.10)  $      (0.13) 
Weighted-average number of common 
 shares outstanding - basic and 
 diluted                                   196,514,267    196,974,508 
 
   (1) exclusive of depreciation 
 
 
 
                           LANZATECH GLOBAL INC. 
                    CONSOLIDATED STATEMENTS OF CASH FLOWS 
                          (Unaudited, in thousands) 
 
                                           Three Months Ended March 31, 
                                      -------------------------------------- 
                                             2025                 2024 
                                                               ---------- 
Cash Flows From Operating 
Activities: 
Net loss                               $      (19,229)      $     (25,508) 
Adjustments to reconcile net loss to 
net cash used in operating 
activities: 
   Share-based compensation expense             2,280               2,529 
   Gain on change in fair value of 
    SAFE and warrant liabilities               (2,932)            (13,277) 
   Loss on Brookfield SAFE 
   extinguishment                               6,216                  -- 
   Loss on change in fair value of 
   the Brookfield Loan                         11,426                  -- 
   Loss on change in fair value of 
    the FPA Put Option and the Fixed 
    Maturity Consideration 
    liabilities                                    --              13,045 
   Gain on change in fair value of 
    Convertible Note                          (35,143)                 -- 
   Provisions for losses on trade 
   and other receivables, net of 
   recoveries                                     126                  -- 
   Depreciation of property, plant 
    and equipment                                 781               1,530 
   Amortization of discount on debt 
    security investment                           (37)               $(360.AU)$ 
   Non-cash lease expense                         490                 496 
   Non-cash recognition of licensing 
    revenue                                    (1,108)               (641) 
   Loss from equity method 
    investees, net                              6,532                 681 
   Unrealized (Gain)/Loss on net 
    foreign exchange                              275                (224) 
Changes in operating assets and 
liabilities: 
   Accounts receivable, net                       240                 645 
   Contract assets                              5,837              (1,029) 
   Accrued interest on debt 
    investment                                     32                (177) 
   Other assets                                   895              (3,012) 
   Accounts payable and accrued 
    salaries and wages                          1,171              (2,207) 
   Contract liabilities                           463                 616 
   Operating lease liabilities                   (467)               (485) 
   Other liabilities                            1,051                (911) 
                                          -----------          ---------- 
      Net cash used in operating 
       activities                             (21,101)            (28,289) 
                                          -----------          ---------- 
Cash Flows From Investing 
Activities: 
Purchase of property, plant and 
 equipment                                       (713)             (1,480) 
Proceeds from maturity of debt 
 securities                                     5,000              10,700 
                                          -----------          ---------- 
      Net cash provided by investing 
       activities                               4,287               9,220 
                                          -----------          ---------- 
Cash Flows From Financing 
Activities: 
Proceeds from issue of equity 
 instruments of the Company                        --                 234 
Repurchase of equity instruments of 
 the Company                                       --                 (48) 
Partial settlement of the Brookfield 
 Loan                                         (12,500)                 -- 
                                          -----------          ---------- 
      Net cash (used in)/provided by 
       financing activities                   (12,500)                186 
Effects of currency translation on 
 cash, cash equivalents and 
 restricted cash                                 (389)                 48 
                                          -----------          ---------- 
Net decrease in cash, cash 
 equivalents and restricted cash              (29,703)            (18,835) 
Cash, cash equivalents and 
 restricted cash at beginning of 
 period                                        45,737              76,284 
                                          -----------          ---------- 
      Cash, cash equivalents and 
       restricted cash at end of 
       period                          $       16,034       $      57,449 
                                          ===========          ========== 
Supplemental disclosure of non-cash 
investing and financing activities: 
Acquisition of property, plant and 
 equipment under accounts payable                 255                 141 
Extinguishment of the Brookfield 
SAFE                                           13,274                  -- 
Issuance of the Brookfield Loan               (19,490)                 -- 
 
 
 
                           LANZATECH GLOBAL INC. 
             Reconciliation of GAAP Net Loss to Adjusted EBITDA 
                          (Unaudited, in thousands) 
 
                                           Three Months Ended March 31, 
                                      -------------------------------------- 
                                             2025                 2024 
                                                               ---------- 
Net Loss                               $      (19,229)      $     (25,508) 
Depreciation                                      781               1,530 
Interest income, net                             (438)             (1,148) 
Stock-based compensation expense and 
 change in fair value of Brookfield 
 SAFE and warrant liabilities (1)                (652)            (10,748) 
Loss on Brookfield SAFE 
extinguishment                                  6,216                  -- 
Change in fair value of the FPA Put 
 Option and Fixed Maturity 
 Consideration liabilities (net of 
 interest accretion reversal)                      --              13,045 
Change in fair value of Convertible 
 Note and related transaction costs           (35,143)                 -- 
Change in fair value of Brookfield 
Loan                                           11,426                  -- 
Loss from equity method investees, 
 net                                            6,532                 681 
                                          -----------          ---------- 
Adjusted EBITDA                        $      (30,507)      $     (22,148) 
                                          ===========          ========== 
 
(1) Stock-based compensation expense represents expense 
 related to equity compensation plans. 
 

Investor Relations Contact

Kate Walsh

VP, Investor Relations & Tax

Investor.Relations@lanzatech.com

(END) Dow Jones Newswires

May 19, 2025 07:00 ET (11:00 GMT)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10